[ad_1]
of The cost of treatment with Cytosorb® Now it is covered by the public sector Turkey
Princeton, NJ, August 23, 2022 /PRNewswire/ — Cytosorbent Corporation (NASDAQ: CTSOThe Turkish Ministry of Health, a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery, has announced a national grant for Cytosorb®. Catalog product in the state supply office Turkey (DMO) portal and can be purchased directly by hospitals and doctors without restrictions.
Dr. Christian SteinerCytosorbents Executive Vice President Sales & Marketing “We are very grateful to the Turkish Ministry of Health for recognizing the important role Cytosorb plays in the management of critically ill or complex patients undergoing cardiovascular surgery. Every year at TurkeyIt is estimated that 140,000 patients are treated in the ICU for severe sepsis or septic shock with a high risk of infection-related mortality. In addition, more than 75,000 patients undergo cardiovascular surgery annually, many of whom are medical tourists treated at private hospitals. In addition, there are many other critically ill patients who suffer from life-threatening conditions such as acute lung or liver failure, trauma, and others. Now with payment, many patients will be using our Cytosorb treatment to add a new dimension to blood purification.
Dr. Steiner praised the strategic partnership with the new distribution partner; Bıçakcılar medical equipment. “Our collaboration with Bıçakcılar was instrumental in achieving national acquisition and inclusion of CytoSorb® in DMO’s healthcare catalog. We look forward to working with them further to leverage our new acquisition and expand the Turkish market for our products.”
Bıçakcılar Medical Equipment is a leading manufacturer of disposable medical products and OR solutions. Turkey. The company was established in 1959. Over the years, the Bikakillar brand has gained wide acceptance and established a culture of continued reliability and customer satisfaction.
Dr. Suhail El HakimCEO of Bıçakcılar, emphasized the importance of both companies’ patient-oriented solutions to improve clinical outcomes in critically ill patients. Turkey And more than that. “We believe that everyone deserves affordable and effective health care. In critical care medicine, with the help of our extensive production facilities, we can distribute the most effective treatments. At the same time, we are working to make a direct impact on health care. In Cytosorbents, we have found one of the most innovative partners to help us achieve this; This gives us the opportunity to fill our presentation with more life.
Turkey Compared to Germany, it provides universal healthcare to 95% of its 84 million citizens. There are over 1,500 hospitals: 62% are public or university hospitals and 38% are private. Turkey The highest number of ICU beds per 100,000 population is about 46, compared to 29 and 39 in the US. Germanyfor example. Turkey It is also the center of medical tourism in the region, attracting 1.7 million patients from abroad Turkey Every year, especially for surgical procedures such as cardiovascular, thoracic, plastic, orthopedic and others.
About Bıçakcılar treatment
Bicalicular medicine It is a 60-year-old company that has created many “firsts”. Turkey Where he was born. Over the years, Bıçakcılar Medical, which has been expanding globally, has helped save lives around the world by providing the most important products in healthcare. From Medical Equipment to OR Solutions, it stands out with two unique features: quality control with zero tolerance for errors and after-sales service by its own experts adds exceptional strength to its medical equipment. The focus on the “patient” is one of the reasons why many of its international and domestic clients have worked with the company for more than 20 years. With more than 800 employees and many business partners, Bıçakcılar serves its customers by manufacturing and supplying innovative, reliable and environmentally friendly medical equipment. Bıçakcılar is committed to ensuring that everything it does benefits the community and the environment while helping to save lives.
Cytosorbent Corporation It is a leader in the treatment of life-threatening conditions in critical care and cardiac surgery. Its main product, Cytosorb®, approved by the European Union and marketed in more than 70 countries worldwide. It is an extracorporeal cytokine delivery designed to reduce the “cytokine storm” or “cytokine release syndrome” that occurs in common critical illnesses and leads to acute inflammation, organ failure, and patient death. In these diseases, the risk of death can be very high, and there are few, if any, effective treatments. In addition, CytoSorb is used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to complications after surgery, including multiple organs. such as June 30, 2022More than 179,000 Cytosorb devices are in total use worldwide. Cytosorb was originally CE-marked in the European Union as the first exogenous cytokine adsorbent. Additional CE Mark extensions for bilirubin and myoglobin in clinical conditions such as liver disease and injury and for ticagrelor And Rivaroxaban Removal during heart surgery. Cytosorb also received. FDA emergency approval in America For use in adults with acute or confirmed respiratory disease in acutely ill COVID-19 patients. The DrugSorb™-ATR antithrombotic removal system, based on the same polymer technology as Cytosorb, has also been adopted. FDA Discovery Device Designation To avoid ticagrelor and FDA Discovery Device Designation For the elimination of direct oral anticoagulants (DOAC) apixaban and rivaroxaban in the cardiopulmonary bypass circuit in emergency cardiothoracic procedures. The company has initiated two pivotal FDA-approved studies to support marketing approval of DrugSorb-ATR in the United States. The first randomized controlled trial, STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor), studied 120 patients at 30 centers to evaluate whether intraoperative use of DrugSorb-ATR could reduce the risk of bleeding in ticagrelor-treated patients undergoing cardiothoracic surgery. The second study Star-D (Safe and Timely Antithrombotic Ablation-Direct Oral Antibiotics) A randomized controlled trial of 120 patients at 30 centers evaluated the intraoperative use of DrugSorb-ATR, including apixaban and rivaroxaban, to reduce the risk of bleeding in patients undergoing cardiac surgery. You are taking antibiotics.
Cytosorbents purification technologies are based on biochemical and highly porous polymer beads that actively remove toxins from blood and other body fluids through pore binding and binding. The company’s technologies are more accepted 39.5 million dollars Through grants, contracts, and other funding from DARPA, the US Department of Health and Human Services (HHS), the National Institutes of Health (NIH), the National Heart, Lung, and Blood Institute (NHLBI), the US Army. , US Air Force, US Special Operations Command (SOCOM), Air Force Materiel Command (USAF/AFMC) and others. The company has several commercialized and in-development products based on this unique blood purification technology, protected by numerous US and international patents and registered trademarks, as well as several pending patent applications, including ECOS-300CY®, CytoSorb-XL™, HemoDefend. RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, DrugSorb™-ATR, ContrastSorb and more. For more information, please visit the company’s websites at www.cytosorbents.com And www.cytosorb.com Or follow us. Facebook And Twitter
Forward-looking statements
This press release It contains forward-looking statements that are qualified by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding our plans, goals, future goals and expectations. Expectations regarding trade, the future impact of Covid-19 or the conflict between them Russia And Ukraine, representations and assurances, and are not historical facts and are generally identified by the use of words such as “will,” “should,” “may,” “expect,” “plan,” “estimate,” “believe,” “”. Anticipate, “predict,” “potential,” “continue” and similar words, although certain forward-looking statements may be defined differently. You should be aware that the forward-looking statements contained in this press release reflect management’s current beliefs and expectations, but that our actual results, events and performance may differ materially from those contained in the forward-looking statements. Factors that could cause or contribute to such differences include the risks described in our Annual Report on Form 10-K filed with the SEC. March 10, 2022, our quarterly reports on Form 10-Q and press releases and other communications from time to time to shareholders to inform relevant parties of our risks and issues. We caution you not to place undue reliance on such forward-looking statements. Except as required by federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Please click to follow us Facebook And Twitter
US company contact:
Amy Vogel
305 College Road East
Princeton, NJ 08540
+1 (732) 329-8885
[email protected]
European company contact:
Josephine Krause
+49 30 765 84 66 23
[email protected]
American Public Relations:
Eric Kim
Rubenstein Public Relations
212-805-3052
[email protected]
European public relations:
Marcus Schultz
Composers
+49 69 13823 ext. 960
+49 172 4238938
[email protected]
Source Cytosorbents Corporation
[ad_2]
Source link
